Lyell Immunopharma, Inc. LYEL

LYEL Company Overview

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell therapies for cancer. The company operates within the oncology and immunotherapy sectors, with a primary emphasis on enhancing the effectiveness and durability of T-cell–based therapies for patients with solid tumors and hematologic malignancies. Lyell’s core strategy centers on engineering immune cells to resist exhaustion and maintain functionality within hostile tumor microenvironments, an area that has historically limited the effectiveness of cellular immunotherapies in solid cancers.

The company’s principal business activities include the research, development, and clinical advancement of engineered T-cell therapies, including chimeric antigen receptor T-cell (CAR-T) and tumor-infiltrating lymphocyte (TIL) technologies. Lyell has positioned itself around proprietary technologies designed to improve T-cell fitness, persistence, and resistance to dysfunction. The company was founded in 2018 and became publicly traded in 2021 through an initial public offering. Since inception, Lyell has evolved from a platform-focused biotechnology company into a clinical-stage organization advancing multiple oncology programs while refining its manufacturing and cellular engineering capabilities.